US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
GB9616237D0
(en)
|
1996-08-01 |
1996-09-11 |
Norton Healthcare Ltd |
Aerosol formulations
|
US6126919A
(en)
*
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US6598603B1
(en)
*
|
1997-12-31 |
2003-07-29 |
Astra Aktiebolag |
Method for treating respiratory diseases
|
SE9804001D0
(sv)
*
|
1998-11-23 |
1998-11-23 |
Astra Ab |
New process
|
IT1303788B1
(it)
*
|
1998-11-25 |
2001-02-23 |
Chiesi Farma Spa |
Formulazioni di aerosol medicinali.
|
DZ2947A1
(fr)
|
1998-11-25 |
2004-03-15 |
Chiesi Farma Spa |
Inhalateur à compteur de dose sous pression.
|
US6319521B1
(en)
*
|
1999-02-10 |
2001-11-20 |
University Technology Corporation |
Microparticles of lactide-co-glycolide copolymers and methods of making and using the same
|
JP4548623B2
(ja)
*
|
1999-02-24 |
2010-09-22 |
多木化学株式会社 |
生体材料
|
CN100370967C
(zh)
*
|
1999-06-04 |
2008-02-27 |
阿尔萨公司 |
埋植凝胶组合物及其制备方法
|
US6315985B1
(en)
*
|
1999-06-18 |
2001-11-13 |
3M Innovative Properties Company |
C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
|
IT1313553B1
(it)
|
1999-07-23 |
2002-09-09 |
Chiesi Farma Spa |
Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
|
ES2230170T3
(es)
*
|
1999-12-15 |
2005-05-01 |
Zimmer Gmbh |
Preparacion para la reparacion de articulaciones en el hombre o el animal, como consecuencia de anomalias cartilaginosas o cartilagino-oseas.
|
US6651655B1
(en)
*
|
2000-01-18 |
2003-11-25 |
Quadrant Technologies Limited |
Inhaled vaccines
|
IT1317846B1
(it)
|
2000-02-22 |
2003-07-15 |
Chiesi Farma Spa |
Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
|
HU230804B1
(hu)
|
2000-05-22 |
2018-06-28 |
Chiesi Farmaceutici S.P.A |
Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
|
CA2417727C
(en)
|
2000-07-31 |
2009-09-01 |
Nycomed Danmark A/S |
Fentanyl composition for nasal administration
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
DE10058829B4
(de)
*
|
2000-11-27 |
2004-08-26 |
3M Espe Ag |
Verwendung von Polysäuren mit enger Molmassenverteilung
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US20030055026A1
(en)
*
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
WO2002092154A1
(en)
|
2001-04-26 |
2002-11-21 |
New England Pharmaceuticals, Inc. |
Metered dose delivery device for liquid and powder agents
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
ATE267591T1
(de)
|
2001-07-02 |
2004-06-15 |
Chiesi Farma Spa |
Optimierte tobramycin-formulierung zur aerosolbildung
|
DE10137102A1
(de)
*
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
US6592899B2
(en)
|
2001-10-03 |
2003-07-15 |
Macromed Incorporated |
PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
|
MXPA04003928A
(es)
*
|
2001-10-26 |
2005-03-31 |
Dey L P |
Solucion para inhalacion de albuterol, sistema, equipo y metodo para aliviar sintomas de asma pediatrica.
|
AU2002367032B8
(en)
*
|
2001-12-21 |
2008-10-23 |
3M Innovative Properties Company |
Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
|
JP2005514437A
(ja)
*
|
2001-12-21 |
2005-05-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
イオン対複合体を含む医薬用エアロゾル製剤
|
EP1455764B1
(en)
*
|
2001-12-21 |
2008-08-27 |
3M Innovative Properties Company |
Medicinal aerosol compositions with an amide and/or ester containing excipient compound
|
EP1340503A1
(en)
*
|
2002-03-01 |
2003-09-03 |
CHIESI FARMACEUTICI S.p.A. |
Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
|
JP2005523905A
(ja)
|
2002-03-01 |
2005-08-11 |
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ |
ホルモテロール(formoterol)超微細調合物
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
PT1531794T
(pt)
*
|
2002-06-28 |
2017-09-14 |
Civitas Therapeutics Inc |
Epinefrina inalável
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
CN1678350A
(zh)
*
|
2002-08-27 |
2005-10-05 |
寺田弘 |
治疗药
|
US6966990B2
(en)
|
2002-10-11 |
2005-11-22 |
Ferro Corporation |
Composite particles and method for preparing
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
SI2218448T1
(sl)
|
2002-12-13 |
2016-01-29 |
Durect Corporation |
Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
US7083748B2
(en)
*
|
2003-02-07 |
2006-08-01 |
Ferro Corporation |
Method and apparatus for continuous particle production using supercritical fluid
|
US6931888B2
(en)
*
|
2003-02-07 |
2005-08-23 |
Ferro Corporation |
Lyophilization method and apparatus for producing particles
|
US20060078504A1
(en)
*
|
2003-02-26 |
2006-04-13 |
Akira Yamamoto |
Sustanined-release pharmaceutical composition for lung administration
|
US20070155926A1
(en)
*
|
2003-03-28 |
2007-07-05 |
Krzysztof Matyjaszewski |
Degradable polymers
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
FR2854071B1
(fr)
*
|
2003-04-25 |
2009-01-30 |
Ethypharm Sa |
Procede de dispersion de substances hydrosolubles ou hydrophiles dans un fluide a pression supercritique
|
US7879357B2
(en)
*
|
2003-04-28 |
2011-02-01 |
Bayer Schering Pharma Ag |
Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
|
US20060008531A1
(en)
*
|
2003-05-08 |
2006-01-12 |
Ferro Corporation |
Method for producing solid-lipid composite drug particles
|
US20040234916A1
(en)
|
2003-05-21 |
2004-11-25 |
Alexza Molecular Delivery Corporation |
Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
|
TWI359675B
(en)
*
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
AU2004312336A1
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Medicinal compositions and method for the preparation thereof
|
US20050271597A1
(en)
*
|
2004-02-13 |
2005-12-08 |
Keith Alec D |
Prostate hypertrophy treatment composition and method
|
EP1595531A1
(en)
|
2004-05-13 |
2005-11-16 |
CHIESI FARMACEUTICI S.p.A. |
Stable pharmaceutical solution formulations for pressurized metered dose inhalers
|
WO2005087819A1
(en)
|
2004-03-05 |
2005-09-22 |
Carnegie Mellon University |
Atom transfer radical polymerization process
|
US7947741B2
(en)
*
|
2004-03-17 |
2011-05-24 |
Mpex Pharmaceuticals, Inc. |
Use and administration of bacterial efflux pump inhibitors
|
US7994225B2
(en)
*
|
2004-03-17 |
2011-08-09 |
Rempex Pharmaceuticals, Inc. |
Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
KR101351771B1
(ko)
|
2004-09-17 |
2014-02-17 |
듀렉트 코퍼레이션 |
바람직하게 saib와 같은 당 에스테르를 포함하는지속적인 국소 마취제 조성물
|
US7115561B2
(en)
*
|
2004-09-22 |
2006-10-03 |
Patterson James A |
Medicament composition and method of administration
|
BRPI0515891A
(pt)
*
|
2004-09-24 |
2008-08-12 |
3 M Innovative Properties Comp |
método para produzir um produto em aerossol medicinal, e, produto em aerossol medicinal
|
JP2008533149A
(ja)
*
|
2005-03-14 |
2008-08-21 |
スリーエム イノベイティブ プロパティズ カンパニー |
医薬用製剤のための生体適合性ポリマー化合物
|
EP1883665B1
(en)
|
2005-04-22 |
2017-10-11 |
Universite De Geneve |
Polylactide compositions and uses thereof
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
US7919583B2
(en)
*
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
US8367734B1
(en)
|
2005-08-11 |
2013-02-05 |
Amphastar Pharmaceuticals Inc. |
Stable epinephrine suspension formulation with high inhalation delivery efficiency
|
EP1928919B1
(en)
|
2005-08-23 |
2010-02-17 |
Carnegie-Mellon University |
Atom transfer radical polymerization in microemulsion and true emulsion polymerization
|
WO2007025310A1
(en)
|
2005-08-26 |
2007-03-01 |
Carnegie Mellon University |
Polymerization process with catalyst reactivation
|
MX2008009125A
(es)
|
2006-01-18 |
2008-10-23 |
Qps Llc |
Composiciones farmaceuticas con estabilidad mejorada.
|
JP2009532339A
(ja)
*
|
2006-03-22 |
2009-09-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
新規製剤
|
EA200801997A1
(ru)
|
2006-04-20 |
2009-04-28 |
Глаксо Груп Лимитед |
Новые соединения
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
US8580307B2
(en)
*
|
2006-06-22 |
2013-11-12 |
Ethicon, Inc. |
High glass transition temperature absorbable microspheres
|
JP2009545579A
(ja)
|
2006-08-01 |
2009-12-24 |
グラクソ グループ リミテッド |
ピラゾロ[3,4−b]ピリジン化合物、及びpde4阻害薬としてのその使用
|
US20080269347A1
(en)
*
|
2006-09-28 |
2008-10-30 |
Azopharma, Inc. |
Epinephrine formulations
|
WO2008057163A2
(en)
|
2006-10-09 |
2008-05-15 |
Carnegie Mellon University |
Preparation of functional gel particles with a dual crosslink network
|
PT2117521E
(pt)
|
2006-11-03 |
2012-09-10 |
Durect Corp |
Sistemas de administração transdérmica que compreendem bupivacaína
|
US20080216828A1
(en)
|
2007-03-09 |
2008-09-11 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
GB2463198B
(en)
|
2007-05-23 |
2013-05-22 |
Univ Carnegie Mellon |
Hybrid particle composite structures with reduced scattering
|
WO2008148000A1
(en)
|
2007-05-23 |
2008-12-04 |
Carnegie Mellon University |
Atom transfer dispersion polymerization
|
WO2008152398A2
(en)
*
|
2007-06-14 |
2008-12-18 |
Cipla Limited |
Formulations for inhalation
|
US8586007B2
(en)
*
|
2007-10-19 |
2013-11-19 |
Wayne State University |
Co-polymer stabilizers for hydrofluoroalkane dispersions
|
WO2009064442A1
(en)
*
|
2007-11-13 |
2009-05-22 |
Brookwood Pharmaceuticals, Inc. |
Viscous terpolymers as drug delivery platform
|
US7979151B2
(en)
*
|
2007-12-06 |
2011-07-12 |
International Business Machines Corporation |
Run-time dispatch system for enhanced product characterization capability
|
AU2008347158B8
(en)
|
2007-12-06 |
2013-08-22 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
AU2008334580A1
(en)
*
|
2007-12-12 |
2009-06-18 |
Basf Se |
Salts of active ingredients with polymeric counter-ions
|
DK2291174T3
(en)
*
|
2008-06-03 |
2015-03-09 |
Tolmar Therapeutics Inc |
Liquid compositions comprising biocompatible oligomer-polymer compositions
|
US8927617B2
(en)
|
2008-06-30 |
2015-01-06 |
Kimberly-Clark Worldwide, Inc. |
Fragranced water-sensitive film
|
US8759279B2
(en)
*
|
2008-06-30 |
2014-06-24 |
Kimberly-Clark Worldwide, Inc. |
Fragranced biodegradable film
|
US20100105140A1
(en)
*
|
2008-07-16 |
2010-04-29 |
Fahrenkrug Scott C |
Plaice dna transposon system
|
WO2010018131A1
(en)
|
2008-08-11 |
2010-02-18 |
Smithkline Beecham Corporation |
Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
KR101649881B1
(ko)
|
2008-08-11 |
2016-08-30 |
글락소스미스클라인 엘엘씨 |
신규의 아데닌 유도체
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
US20100168807A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Burton Kevin W |
Bioactive terpolymer compositions and methods of making and using same
|
US20100158978A1
(en)
*
|
2008-12-23 |
2010-06-24 |
Peter Markland |
Bioactive spray coating compositions and methods of making and uses thereof
|
US9415197B2
(en)
|
2008-12-23 |
2016-08-16 |
Surmodics, Inc. |
Implantable suction cup composites and implants comprising same
|
US8951546B2
(en)
|
2008-12-23 |
2015-02-10 |
Surmodics Pharmaceuticals, Inc. |
Flexible implantable composites and implants comprising same
|
US8974808B2
(en)
*
|
2008-12-23 |
2015-03-10 |
Surmodics, Inc. |
Elastic implantable composites and implants comprising same
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
EP2408915A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
CN102439151A
(zh)
|
2009-03-19 |
2012-05-02 |
默沙东公司 |
使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
SG174581A1
(en)
|
2009-03-27 |
2011-10-28 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111708A1
(en)
|
2009-03-27 |
2010-09-30 |
Carnegie Mellon University |
Preparation of functional star macromolecules
|
JP2012521764A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
|
EP2411019A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
CA2756072A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
WO2010122089A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as crac channel inhibitors
|
MX2012005711A
(es)
|
2009-11-17 |
2012-10-05 |
Cipla Ltd |
Soluciones de inhalacion.
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
US9993441B2
(en)
|
2009-12-30 |
2018-06-12 |
Surmodics, Inc. |
Controlled release matrix barrier structure for subcutaneous medical devices
|
WO2011098451A1
(en)
|
2010-02-10 |
2011-08-18 |
Glaxosmithkline Llc |
Purine derivatives and their pharmaceutical uses
|
ES2525826T3
(es)
|
2010-02-10 |
2014-12-30 |
Glaxosmithkline Llc |
Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI)
|
WO2012030819A1
(en)
|
2010-08-30 |
2012-03-08 |
Surmodics Pharmaceuticals, Inc. |
Terpolymers as pressure-sensitive adhesives
|
US9113916B2
(en)
|
2010-08-31 |
2015-08-25 |
Zimmer, Inc. |
Drill bit for osteochondral drilling with guiding element and uses thereof
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
JP5795643B2
(ja)
|
2010-10-21 |
2015-10-14 |
グラクソ グループ リミテッドGlaxo Group Limited |
アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
WO2012091965A1
(en)
|
2010-12-17 |
2012-07-05 |
Carnegie Mellon University |
Electrochemically mediated atom transfer radical polymerization
|
JP2014516062A
(ja)
|
2011-06-08 |
2014-07-07 |
グラクソ グループ リミテッド |
ウメクリジニウム及びコルチコステロイドを含む組合せ
|
EP2747753B1
(en)
|
2011-08-22 |
2023-03-29 |
Carnegie Mellon University |
Atom transfer radical polymerization under biologically compatible conditions
|
JP2014532717A
(ja)
*
|
2011-11-03 |
2014-12-08 |
プレシジョン ダーマトロジー インコーポレイテッドPrecision Dermatology, Inc. |
反応性噴射剤を使用した安定な皮膚用エアゾールフォーム
|
US9533297B2
(en)
|
2012-02-23 |
2017-01-03 |
Carnegie Mellon University |
Ligands designed to provide highly active catalyst complexes
|
EP2836204B1
(en)
|
2012-04-13 |
2020-07-08 |
GlaxoSmithKline Intellectual Property Development Limited |
Aggregate particles
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
EP3563849A3
(en)
|
2012-10-25 |
2020-02-12 |
The General Hospital Corporation |
Combination therapies for the treatment of alzheimer's disease and related disorders
|
US10058530B2
(en)
|
2012-10-25 |
2018-08-28 |
The General Hospital Corporation |
Combination therapies for the treatment of Alzheimer's disease and related disorders
|
AU2013356383B2
(en)
|
2012-12-06 |
2017-08-31 |
Merck Sharp & Dohme Corp. |
Disulfide masked prodrug compositions and methods
|
EP2983468A4
(en)
|
2013-03-15 |
2016-09-07 |
Durect Corp |
COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
|
EP2999337A4
(en)
|
2013-05-23 |
2017-03-15 |
Aztherapies, Inc |
Methods for delivering cromolyn
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
EP3060205A4
(en)
|
2013-10-22 |
2017-06-28 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
JP6564369B2
(ja)
|
2013-12-09 |
2019-08-21 |
デュレクト コーポレイション |
薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
|
CN106456595A
(zh)
|
2014-02-10 |
2017-02-22 |
帕塔拉制药有限责任公司 |
用于系统性病症的肥大细胞稳定剂治疗
|
HUE049323T2
(hu)
|
2014-02-10 |
2020-09-28 |
Respivant Sciences Gmbh |
Hízósejt-stabilizálók tüdõbetegség kezelésére
|
EP3107915B1
(en)
|
2014-02-20 |
2017-11-08 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
|
WO2015143357A2
(en)
*
|
2014-03-21 |
2015-09-24 |
Boston Scientific Scimed, Inc. |
Devices and methods for treating a lung
|
AU2015338717B2
(en)
|
2014-10-31 |
2018-12-20 |
Glaxosmithkline Intellectual Property Development Limited |
Powder formulation
|
JP2017533925A
(ja)
|
2014-11-13 |
2017-11-16 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
|
US9982070B2
(en)
|
2015-01-12 |
2018-05-29 |
Carnegie Mellon University |
Aqueous ATRP in the presence of an activator regenerator
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
CA3004492A1
(en)
|
2015-11-18 |
2017-05-26 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pharmaceutical compositions of ribavirin
|
MA52157A
(fr)
|
2015-12-03 |
2021-02-17 |
Glaxosmithkline Ip Dev Ltd |
Dinucléotides cycliques de purine utilisés comme modulateurs de sting
|
AU2016370779B2
(en)
|
2015-12-17 |
2019-07-25 |
Astex Therapeutics Limited |
Quinoline-3-carboxamides as H-PGDS inhibitors
|
CA3033079A1
(en)
|
2016-08-31 |
2018-03-08 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
JP2019528320A
(ja)
|
2016-08-31 |
2019-10-10 |
レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh |
特発性肺線維症による慢性咳の治療のためのクロモリン組成物
|
JP2019531308A
(ja)
|
2016-10-07 |
2019-10-31 |
レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh |
肺線維症の治療のためのクロモリン組成物
|
US11174325B2
(en)
|
2017-01-12 |
2021-11-16 |
Carnegie Mellon University |
Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
|
WO2019017995A1
(en)
|
2017-07-20 |
2019-01-24 |
Aztherapies, Inc. |
FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
|
US20210038563A1
(en)
|
2018-01-26 |
2021-02-11 |
Apidel Sa |
New spironolactone formulations and their use
|
SG11202012765PA
(en)
|
2018-06-22 |
2021-01-28 |
Ucl Business Ltd |
Novel compounds
|
CN113038944A
(zh)
|
2018-07-02 |
2021-06-25 |
通用医疗公司 |
色甘酸钠和α-乳糖的粉末化制剂
|
WO2021146215A1
(en)
|
2020-01-13 |
2021-07-22 |
Durect Corporation |
Sustained release drug delivery systems with reduced impurities and related methods
|